DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...

Advancements in precision medicine drive the 5-HT2 agonist market by enabling selective targeting of specific receptor subtypes (e.g., 5-HT2A or 5-HT2C), reducing side effects and improving safety.

This article will explore what DLBCL is and how clinical trials can potentially lead to breakthroughs in treatment.

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ( ...

Cancer and its associated treatments represent a multifaceted challenge that affects both the physical and psychological well-being of patients. Over the ...

In this interview, we explore the key changes shaping the pharmaceutical industry, maintaining compliance across global ...

New research highlights concerns about sleep aids disrupting the brain's cleaning process and their long-term effects on ...

Though Brazil has the expertise and infrastructure, clinical research is not at the level that might be expected of the world’s fifth-most-populous country. Luis Magalhaes and Le Vin Chin ...